Abstract
Lipoprotein(a) (Lp[a]) is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD). Lp(a) concentration is predominantly genetically determined, and has been suggested to remain stable over an individual’s lifetime. The 2021 Canadian Cardiovascular Society dyslipidemia guidelines recommend measuring Lp(a) once in a patient’s lifetime to assess ASCVD risk, given the assumption of biological stability, and because there is no current treatment to reduce Lp(a) nor evidence that reduction is beneficial.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
